logo
Digging deeper: Saskatchewan producers look for greener way to mine lithium

Digging deeper: Saskatchewan producers look for greener way to mine lithium

CBC3 days ago
Saskatchewan is home to large lithium deposits and a handful of the province's mining companies are betting on a green approach to take them global.
Lithium is the main element in batteries, powering everything from smartphones to electric vehicles (EVs), which made up 17 per cent of all new cars sold in Canada in 2024.
According to the United States Geological Survey, the global demand for lithium was up by nearly 18 per cent last year.
"Demand is expected to continue to grow and that's coming mainly in the form of EVs," said Paul Schubach, chief operating officer for EMP Metals Corporation.
He said there's a strong international interest in lithium, of which nearly 95 per cent of the metal comes from countries like Australia, Chile, China and Argentina.
The majority of the mineral is then processed in China, which dominates the manufacturing of electric vehicle batteries.
Schubach said Canada is far behind when it comes to producing lithium.
" There's a lot of attention right now on North America and the EV boom that was expected to be there just hasn't quite taken off yet," he said.
Environmental concerns around mining lithium
There are many ways that lithium can be mined, but not all of them are environmentally safe.
For instance, in South America, lithium is mined through expansive salt pools that hold salty water containing metals and minerals.
In places like Chile, Bolivia and Argentina, the salty water is pumped to the surface, where it sits in massive pools to naturally evaporate, separating lithium from the other minerals.
However, the extraction of brine has been found to reduce water levels in these areas, which can contaminate water sources with dangerous materials, becoming a danger to humans and animals who depend on it.
The other common way of getting lithium is strip mining, or open pit mining, where lithium is removed by digging into hard rock below the ground.
This can cause groundwater to dry up in nearby lakes, rivers and streams.
There's also toxic chemicals used that can leak into water sources if not properly managed.
With so many risks, some experts say that while extracting lithium is important, it shouldn't be thought of as a magic solution to climate change just because it powers the EV industry.
What does that mean for Saskatchewan?
It's no secret to Saskatchewan producers that lithium production can pose a harm to the environment.
That's why a handful of companies in the province are looking to change that by pioneering a new way of getting the mineral out of the ground.
Benjamin Sparrow, CEO of Saltworks Technologies, said instead of using traditional methods like hard rock mining or strip mining, more producers are now using direct lithium extraction (DLE), which takes it right out of the ground, separates out the lithium and recycles the groundwater.
"It's underway and specifically underway in Canada," Sparrow said.
He said DLE has the smallest environmental footprint and a "very small" land footprint for wells, electricity and water.
Evaporation ponds are often not using a freshwater resource. Instead, Sparrow said they use a brine that is not intended for farming, drinking or other means because it's low-quality water.
"The environmental footprint is largely associated with the ponds themselves, and as long as the ponds and the geotech is done right, there should not be any environmental concerns," he said.
Teresa Kramarz, a mining expert at the University of Toronto, cautions this type of technology is still being tested and has yet to be tried on a large commercial scale in Saskatchewan.
She said while in theory it uses less water and land, it needs to be studied further.
There's not a lot of research to demonstrate whether direct extraction uses less water than the salt ponds in South America, Kramarz said.
She said the potential for the technology is promising, but it remains to be seen if it will be cost effective and widely used.
What's stopping Saskatchewan's lithium industry from starting commercial production?
Sparrow said what stands out about Saskatchewan's resource is there's a high concentration of lithium and it's close to the surface, so it's very cost effective to extract.
Areas like Kindersley and Estevan, both have large reserves of an underground brine, or water, that contains lithium.
Additionally, Sparrow points to the province's infrastructure and labour available from the oil and gas industry, which isn't the case for other regions.
At the same time, the current cost for lithium is $8,000 to $10,000 a ton.
Sparrow said while the low cost makes DLE technology not the most economic, that hasn't put a damper on the Saskatchewan mining industry.
"Innovation can change the cost equation," Sparrow said. "And that's exactly the work that's underway in Saskatchewan to drive the cost down below today's market price."
Saskatchewan mining companies are betting the demand for lithium will quickly outpace supply.
Schubach said he is confident that will happen.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CVRx (CVRX) Q2 Revenue Jumps 15%
CVRx (CVRX) Q2 Revenue Jumps 15%

Globe and Mail

time27 minutes ago

  • Globe and Mail

CVRx (CVRX) Q2 Revenue Jumps 15%

Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025

Scott Moe speaks out against AI ‘deepfakes' of him circulating online
Scott Moe speaks out against AI ‘deepfakes' of him circulating online

CTV News

timean hour ago

  • CTV News

Scott Moe speaks out against AI ‘deepfakes' of him circulating online

Saskatchewan Premier Scott Moe listens to a question from the media during the 2025 summer meetings of Canada's Premiers at Deerhurst Resort in Huntsville, Ont., on Wednesday, July 23, 2025. THE CANADIAN PRESS/Nathan Denette Saskatchewan Premier Scott Moe says his government is doing whatever it can to track down the creators of so-called 'deepfakes' of him and other prominent figures. Moe's likeness, including his voice, has been used in online video ads for cryptocurrency schemes that he says he would never endorse. The premier says on his official social media that some of the videos, which are created with artificial intelligence, feature him and others, including Prime Minister Mark Carney. Moe says his government is doing its best to find the people behind the videos, but adds it can be difficult to prevent the scams. It's not the first time Moe's image has been used to market the scams — he first acknowledged them in March. Saskatchewan's consumer watchdog has been issuing warnings about the impersonation scams and urges people not to send money to companies that aren't registered in the province. This report by The Canadian Press was first published Aug. 4, 2025.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store